Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials

1. Mateos, M.-V.
2. Goldschmidt, H.
3. San-Miguel, J.
4. Mikhael, J.
5. DeCosta, L.
6. Zhou, L.
7. Obreja, M.
8. Blaedel, J.
9. Szabo, Z.
10. Leleu, X.